metastatic/advanced RCC (mRCC) - 2nd line (L2) | |
metastatic/advanced RCC (mRCC) - 2nd line (L2) | |
anti-PD-(L)1 | |
atezolizumab based treatment | |
atezolizumab plus cabozantinib | CONTACT-03 |
nivolumab based treatment | |
nivolumab alone | CheckMate 025 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -